BofA lowered the firm’s price target on Sana Biotechnology to $11 from $13 and keeps a Buy rating on the shares. Sana had another "quiet quarter," but 2023 is setting up to be eventful for the company as it begins to initiate clinical studies, the analyst tells investors in a research note. The firm have updated its forecasts to reflect Sana’s recent pipeline prioritization and current cash position.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SANA:
- Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
- Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
- Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference
- Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
- Sana says FDA okays new new drug IND application for SC291 B-cell study